Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
Journal for ImmunoTherapy of Cancer · 2023-05 · 11 (5) · e006290
DOI: 10.1136/jitc-2022-006290 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 23.05.2023. Verfasst von Luc Magré und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 196-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences & Health) grant.
Abstract (Originalsprache)
In the past decade, treatments targeting the immune system have revolutionized the cancer treatment field. Therapies such as immune checkpoint inhibitors have been approved as first-line treatment in a variety of solid tumors such as melanoma and non-small cell lung cancer while other therapies, for instance, chimeric antigen receptor (CAR) lymphocyte transfer therapies, are still in development. Although promising results are obtained in a small subset of patients, overall clinical efficacy of most immunotherapeutics is limited due to intertumoral heterogeneity and therapy resistance. Therefore, prediction of patient-specific responses would be of great value for efficient use of costly immunotherapeutic drugs as well as better outcomes. Because many immunotherapeutics operate by enhancing the interaction and/or recognition of malignant target cells by T cells, in vitro cultures using the combination of these cells derived from the same patient hold great promise to predict drug efficacy in a personalized fashion. The use of two-dimensional cancer cell lines for such cultures is unreliable due to altered phenotypical behavior of cells when compared with the in vivo situation. Three-dimensional tumor-derived organoids, better mimic in vivo tissue and are deemed a more realistic approach to study the complex tumor–immune interactions. In this review, we present an overview of the development of patient-specific tumor organoid-immune co-culture models to study the tumor-specific immune interactions and their possible therapeutic infringement. We also discuss applications of these models which advance personalized therapy efficacy and understanding the tumor microenvironment such as: (1) Screening for efficacy of immune checkpoint inhibition and CAR therapy screening in a personalized manner. (2) Generation of tumor reactive lymphocytes for adoptive cell transfer therapies. (3) Studying tumor–immune interactions to detect cell-specific roles in tumor progression and remission. Overall, these onco-immune co-cultures might hold a promising future toward developing patient-specific therapeutic approaches as well as increase our understanding of tumor–immune interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
- Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands j.desai@erasmusmc.nl.
Förderung
- TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences & Health) grant
Zitieren
APA
Magré, L., Verstegen, M. M. A., Buschow, S., van der Laan, L. J. W., Peppelenbosch, M., & Desai, J. (2023). Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. Journal for ImmunoTherapy of Cancer, 11(5), e006290. https://doi.org/10.1136/jitc-2022-006290
Vancouver
Magré L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. Journal for ImmunoTherapy of Cancer. 2023;11(5):e006290. doi:10.1136/jitc-2022-006290
BibTeX
@article{Magr2023,
author = {Magré, Luc and Verstegen, Monique M A and Buschow, Sonja and van der Laan, Luc J W and Peppelenbosch, Maikel and Desai, Jyaysi},
title = {Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {5},
pages = {e006290},
doi = {10.1136/jitc-2022-006290}
}
EUVIMED